1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Expert Analysis: EU Commission's Proposed Regulation On Health Technology Assessment

An HTA proposal from the European Commission represents a new step toward harmonized market access for health technologies in the EU. Simmons & Simmons lawyers Annabelle Bruyndonckx and Vladimir Murovec provide an expert view on the proposal, its impact on the medtech sector and how it relates to the EU Medical Device and IVD Regulations.

Concept of national healthcare system - EU - European Union
About The Authors

Annabelle Bruyndonckx is a counsel with Simmons & Simmons LLP, focusing on all parts of medicinal product and medical device lifecycles, from R&D and qualification, to marketing authorization/CE-marking, to pricing & reimbursement, manufacture and distribution, compliance, and more.

Vladimir Murovec is an associate with Simmons & Simmons LLP, advising on a wide range of regulatory issues relating to medicines, medical technologies and digital health solutions, including product qualification, (early) market access procedures, marketing, distribution, advertising, and monitoring of products.

On Jan. 31, the EU Commission published a proposal for a regulation (the "Draft Regulation") on health technology assessments (HTA; SWD[2018] 42 final) and amending a 2011 Cross-Border Healthcare Directive (CBD; 2011/24/EU). Also see "Revolutionary EU HTA Cooperation Proposal Will Use MDR/IVDR Platforms" - Medtech Insight, 1 February, 2018.

This draft HTA regulation builds on the collaboration and methodology pursued for more than 10 years by the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Investors Urged To Prioritize Patient Engagement To Ensure Clients’ Products Succeed

 
• By Amanda Maxwell

To succeed in medtech, investors must focus on patient outcomes. Gilde Healthcare says involving patients boosts product effectiveness, access and market success — making it a smart strategy in today’s strained healthcare systems.

EU Life Sciences Strategy Must Address ‘Regulatory Lasagna’

 
• By Amanda Maxwell

MedTech Europe is ready to become involved and shape Europe’s Life Sciences Strategy and help drive regulatory simplification from the top to make the EU “the world’s most attractive place for life sciences by 2030.”

FDA Publishes Final Cybersecurity Guidance To Replace Final Cybersecurity Guidance

 
• By Brian Bossetta

The US FDA has issued an updated final guidance document on cybersecurity considerations for medical device manufacturers that replaces a previous final guidance the agency issued in 2023.

New Regulation Significantly Expands eIFU Usage Scope

 
• By Amanda Maxwell

Amendment brings new benefits for device accessories and aesthetic devices used by healthcare professionals.

More from Policy & Regulation

Deaths And Serious Injuries Linked To A Pair Of Heart Device Recalls

 
• By Brian Bossetta

Two recent recalls from the US FDA involve three deaths linked to an issue with an Abiomed heart pump — as well as three serious injuries related to angiographic catheters from Cook Medical.

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By Marion Webb

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

June 2025: A Bumper Month For New EU Medtech Documents And Initiatives

 
• By Amanda Maxwell

The rate at which new documents to support the implementation of EU medtech regulations are issued has slowed of late; but June bucked the trend, with a flurry of activity.